Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog.

Area of Science:

• Oncology
• Radiotherapy
• Drug Development

Background:

• Antitumor alkyl phospholipid (APL) analogs exhibit tumor selectivity.
• Some APLs demonstrate radiosensitizing properties.
• CLR127 is a novel, clinical-grade synthetic APL ether analog with targeted cancer cell uptake.

Purpose of the Study:

• To evaluate the radiosensitizing effects of CLR127 in various adult and pediatric cancers.
• To assess CLR127's impact on radiation response in vitro and in vivo.

Main Methods:

• In vitro studies using cancer cell lines and normal cells.
• Murine xenograft models of human prostate adenocarcinoma, neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma.
• Assessment of clonogenic survival, DNA double-strand breaks, and tumor regrowth post-radiotherapy.

Main Results:

• CLR127 showed selective uptake in cancer cells versus normal cells.
• Pre-treatment with CLR127 significantly reduced cancer cell survival post-radiation and increased DNA dsDNA breakage.
• CLR127 enhanced antitumor response to fractionated radiotherapy and delayed tumor regrowth in animal models.

Conclusions:

• CLR127 effectively enhances radiation response across multiple cancer types.
• The universal uptake in malignant cells supports broad applicability.
• CLR127 presents a strong rationale for clinical investigation as a tumor-targeted radiosensitizer.